

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10724266	
	Filing Date		2003-11-26	
	First Named Inventor	ENENKEL, Barbara		
	Art Unit	1636		
	Examiner Name	James S. Ketter		
	Attorney Docket Number	1/1412		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	5412216	A1	1995-05-02	Dodson, Jr.		
	2	5122458	A1	1992-06-16	Post et al.		
	3	6060273	A1	2000-05-09	Dirks et al.		

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	20030219871	A1	2003-11-27	Enenkel et al.		

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	0393438	EP	A2	1990-10-24	Boehringer Ingelheim International GmbH		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10724266
Filing Date		2003-11-26
First Named Inventor	ENENKEL, Barbara	
Art Unit	1636	
Examiner Name	James S. Ketter	
Attorney Docket Number	1/1412	

	2	0953639	EP	A1	1999-11-03	Boehringer Ingelheim International GmbH		<input type="checkbox"/>
	3	9208796	WO	A1	1992-05-29	Immunex Corporation		<input type="checkbox"/>
	4	9405785	WO	A1	1994-03-17	Wilhelm Dirks et al.		<input type="checkbox"/>
	5	9428143	WO	A1	1994-12-08	Targeted Genetics Corporation		<input type="checkbox"/>
	6	0034318	WO	A1	2000-06-15	Clontech Laboratories, Inc.		<input type="checkbox"/>
	7	0034326	WO	A1	2000-06-15	Clontech Laboratories, Inc.		<input type="checkbox"/>
	8	0034526	WO	A1	2000-06-15	Clontech Laboratories, Inc.		<input type="checkbox"/>
	9	0127150	WO	A2	2001-04-19	Clontech Laboratories, Inc.		<input type="checkbox"/>
	10	195 39 493	DE	A1	1997-04-30	Dr. Karl Thomae GmbH		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

**NON-PATENT LITERATURE DOCUMENTS**

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
--------------------	---------	---	----------------

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10724266
Filing Date	2003-11-26
First Named Inventor	ENENKEL, Barbara
Art Unit	1636
Examiner Name	James S. Ketter
Attorney Docket Number	1/1412

1	MANFRED GOSSEN ET AL; Inducible Gene Expression Systems for Higher Eukaryotic Cells; Current Opinion in Biotechnology (1994) Vol. 5 pages 516-520; Current Biology Ltd.	<input type="checkbox"/>
2	SHI-ZHEN HU ET AL; Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-CH3) which Exhibits Rapid, High-Level Targeting of Xenografts; Cancer Research (1996) Vol. 56 pages 3055-3061.	<input type="checkbox"/>
3	JAMES S. HUSTON ET AL; Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in Escherichia Coli; Proceedings of the National Academy of Sciences of the United States of America (1988) Vol. 85 pages 5879-5883.	<input type="checkbox"/>
4	ALEXANDER A. KORTT ET AL; Single-Chain Fv Fragments of Anti-Neuraminidase Antibody NC10 Containing Five- and Ten-Residue Linkers Form Dimers and with Zero-Residue Linker a Trimer; Protein Engineering (1997) Vol. 10 No. 4 pages 423-433.	<input type="checkbox"/>
5	BRETT LOVEJOY ET AL; crystal structure of a Synthetic Triple-Stranded Helical Bundle; Research Article (1993) Vol. 259 pages 1288-1293.	<input type="checkbox"/>
6	YASUMI OHSHIMA ET AL; Signals for the Selection of a Splice in Pre-mRNA Computer Analysis of Splice Junction Sequences and Like Sequences; Journal Molecular Biology (1987) Vol. 195 pages 247-259.	<input type="checkbox"/>
7	PETER PACK ET AL; Tetravalent Miniantibodies with High Avidity Assembling in Escherichia Coli; Journal Molecular Biology (1995) Vol. 246 pages 28-34; Academic Press Limited.	<input type="checkbox"/>
8	OLGA PERISIC ET AL; Crystal Structure of a Diabody, a Bivalent Antibody Fragment; Structure (1994) Vol. 2 pages 1217-1226; Current Biology Ltd.	<input type="checkbox"/>
9	M. WIGLER ET AL; Transformation of Mammalian Cells with an Amplifiable Dominant-Acting Gene; Proceedings of the National Academy of Sciences of the United States of America (1980) Vol. 77 No. 6 pages 3567-3570.	<input type="checkbox"/>
10	JORDI BELLA ET AL; Review: Rhinoviruses and Their ICAM Receptors; Journal of Structural Biology (1999) Vol. 128 pages 69-74; Academic Press.	<input type="checkbox"/>
11	STEVEN D. MARLIN ET AL; A Soluble Form of Intercellular Adhesion Molecule-1 Inhibits Rhinovirus Infection; Nature (1990) Vol. 344 pages 70-77.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10724266
Filing Date	2003-11-26
First Named Inventor	ENENKEL, Barbara
Art Unit	1636
Examiner Name	James S. Ketter
Attorney Docket Number	1/1412

12	GARRY P. NOLAN ET AL; Fluorescence-Activated Cell Analysis and Sorting of Viable Mammalian Cells based on B-D-Galactosidase Activity After Transduction of Escherichia Coli LacZ; Proceedings of the National Academy of Sciences of the United States of America (1988) Vol. 85 pages 2603-2607	<input type="checkbox"/>
13	CHRISTIAN C. SIMONSEN ET AL; Isolation and Expression of an Altered Mouse Dihydrofolate Reductase cDNA; Proceedings of the National Academy of Sciences of the United States of America (1983) Vol. 80 pages 2495-2499.	<input type="checkbox"/>
14	STEFFEN FAISST ET AL; Compilation of Vertebrate-Encoded Transcription Factors; Nucleic Acids Research (1992) Vol. 20 No. 1 pages 3-26; Oxford University Press.	<input type="checkbox"/>
15	PETER PACK ET AL; Improved Bivalent Miniantibodies, with identical Avidity as whole Antibodies, Produced by High Cell Density Fermentation of Escherichia Coli; Bio/Technology (1993) Vol. 11 pages 1271- 1277; Nature Publishing Group.	<input type="checkbox"/>
16	DANIEL A HABER ET AL; Chromosome-Mediated Transfer and Amplification of an Altered Mouse Dihydrofolate Reductase Gene; Somatic Cell Genetics (1982) Vol. 8 No. 4 pages 499-508; Plenum Publishing Corporation.	<input type="checkbox"/>
17	Austrian Search Report and Written Opinion for 200503275-0 mailed on September 7, 2006	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10724266
Filing Date	2003-11-26
First Named Inventor	ENENKEL, Barbara
Art Unit	1636
Examiner Name	James S. Ketter
Attorney Docket Number	1/1412

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☒ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Edouard G. Lebel/	Date (YYYY-MM-DD)	2007-08-06
Name/Print	Edouard G. Lebel	Registration Number	43742

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.